WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...
Meixell, AstraZeneca director of corporate communications. “As we announced in March, we will redesign the Wilmington site to accommodate business needs and the employee population, eventually ...
WILMINGTON, Del., January 17, 2025--AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with ...
BallerAlert on MSN4mon
HBCU Week Foundation Announces 8th Annual HBCU Week in Wilmington and College Fair at Walt Disney WorldThe HBCU Week Foundation is gearing up for its 8th annual HBCU Week Wilmington (DE), presented by AstraZeneca, running from September 22-29, 2024. In addition to the Wilmington festivities ...
WILMINGTON, Del., December 08, 2024--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a ...
Named the winner of the Josiah Marvel Cup, retired U.S. Senator Tom Carper was recognized this evening for his almost half century of service during the 188th Delaware State Chamber ...
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback